一分钟看懂
这是一项关于肺癌的III 期研究，登记的药物或干预包括TAS6417；Zipalertinib Matching-placebo，当前状态为研究进行中，已停止招募。登记地点显示中国Anchorage、Duarte、Irvine、La Jolla等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
TAS6417；Zipalertinib Matching-placebo · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Alaska Oncology and Hematology · Anchorage
- City of Hope Comprehensive Cancer Center - Duarte · Duarte
- City of Hope Comprehensive Cancer Center Orange County Lennar Foundation Cancer Center · Irvine
- Scripps Clinic Torrey Pines · La Jolla
- Kaiser Permanente - Vallejo Medical Center · Vallejo
- Georgetown University School of Medicine · Washington D.C.
- D&H Cancer Research Center - Margate · Margate
- Alpha Oncology Research · Orange City
- City of Hope - Atlanta · Newnan
- University of Illinois Medical Center · Chicago
- Profound Research LLC at Michigan Hematology and Oncology Consultants · Dearborn
- Henry Ford Health System · Detroit
- Memorial Sloan Kettering Cancer Center - Basking Ridge · Basking Ridge
- Memorial Sloan Kettering Cancer Center - Monmouth · Middletown
- Memorial Sloan Kettering Cancer Center - Bergen · Montvale
- Memorial Sloan Kettering Cancer Center - Commack · Commack
- Memorial Sloan Kettering Cancer Center - Westchester · East White Plains
- Long Island Jewish Medical Center · Lake Success
- Perlmutter Cancer Center - 34th Street · New York
- Memorial Sloan Kettering Cancer Center - New York · New York
- Memorial Sloan Kettering Cancer Center - Nassau · Uniondale
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center · Charlotte
- Durham Veterans Affairs Health Care System · Durham
- Gabrail Cancer and Research Center · Canton
- Gibbs Cancer Center and Research Institute Spartanburg · Spartanburg
- Virginia Cancer Specialists - Arlington Office · Arlington
- Virginia Cancer Specialists - Fairfax Office · Fairfax
- Virginia Cancer Specialists - Bristow Office · Manassas
- Virginia Cancer Specialists - Reston · Reston
- Virginia Cancer Specialists - Woodbridge Office · Woodbridge
公开的入选条件
- 1. Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
- 2. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States \[US\]) or accredited (outside of the US) local laboratory, defined as either one of the following EGFRmt:
- 1. exon20 insertion mutations (ex20ins) or
- 2. other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) exons 18-21 of the EGFR tyrosine kinase domain
- 3. Baseline imaging assessment of the brain (MRI \[preferred modality\] or CT scan) performed within 8 weeks prior to randomization must show no evidence of brain metastasis
- 4. Complete surgical resection of the primary NSCLC is mandatory with negative surgical margins and systematic lymph node sampling or dissection.
- 5. Complete recovery from surgery, including post-operative wound healing, and prior adjuvant chemotherapy (if applicable) at the time of randomization. Randomization timing is defined as follows:
- 1. For participants without prior adjuvant chemotherapy: 4 weeks and 12 weeks following surgery.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07128199；登记信息更新于 2026-08-26。